| |
| |
|
Developing vaccines for cancer is a scientific holy grail, and Moderna, the company behind one of the COVID shots, has taken a big leap toward that goal. Its experimental personalized melanoma vaccine, developed with Merck and given with the immunotherapy drug Keytruda, reduced the risk of recurrence by 42%.
|
|
For her new TIME feature, my colleague Alice Park goes behind the scenes with Moderna’s CEO, Stéphane Bancel, drawing on years of interviews. She tracks the rise of this pioneering company and the man who runs it.
|
|
|
TODAY’S TOPICS
|
|
|
|
|
|
| |
|
|
|
| |
| |
WHAT’S GOING AROUND?
|
RSV is rising
|
 |
|
Computer illustration of respiratory syncytial virus (RSV). Kateryna Kon/Science Photo Library—Getty Images
|
|
|
Cases of respiratory syncytial virus (RSV) have started to climb nationally, mostly in children under the age of 5, according to the U.S. Centers for Disease Control and Prevention (CDC).
|
|
RSV usually causes mild, cold-like symptoms such as a runny nose and cough. But it can be severe, particularly in high-risk people including infants and older adults. RSV is the leading cause of infant hospitalization.
|
|
The American Academy of Pediatrics (AAP) recommends the RSV vaccine for infants under 8 months old if their mother didn’t receive an RSV shot during pregnancy. Children aged 8 months to 19 months at high risk of RSV, including those with chronic lung conditions, are also encouraged to get vaccinated even if they’ve received the shot before.
|
|
For adults, the CDC recommends that everyone above the age of 75 get the RSV vaccine. People over the age of 50 who are at risk of severe RSV illness should also get the shot, the CDC says. For most people, the RSV vaccine is one-dose, lifetime shot. —Dominique Mosbergen
|
|
|
|
| |
|
|
|
| |
| |
SPONSORED BY THE DEEP VIEW
|
Stop Drowning In AI Information Overload
|
|
|
|
Your inbox is flooded with newsletters. Your feed is chaos. Somewhere in that noise are the insights that could transform your work—but who has time to find them?
|
|
The Deep View solves this. We read everything, analyze what matters, and deliver only the intelligence you need. No duplicate stories, no filler content, no wasted time. Just the essential AI developments that impact your industry, explained clearly and concisely.
|
|
Replace hours of scattered reading with five focused minutes. While others scramble to keep up, you'll stay ahead of developments that matter. 600,000+ professionals at top companies have already made this switch.
|
|
Join them today, for free.
|
|
|
|
|
|
| |
|
|
|
| |
| |
A GOOD READ
|
The next chapter of mRNA
|
 |
|
Stéphane Bancel, CEO of Moderna, in the Moderna headquarters office in Cambridge, Mass. on Oct. 19, 2026. Tony Luong for TIME
|
|
|
It’s been a very good year for Stéphane Bancel. On a crisp October day, the CEO of Moderna, of COVID-vaccine fame, is sitting in his glass-walled office in the company’s headquarters in Cambridge, Mass., weeks before encouraging results from the company’s first mRNA cancer vaccine would become public. He’s recounting the biotech’s rocky road turning an unproven, scientifically dismissed approach—using messenger RNA, or mRNA, the genetic code that instructs cells to make proteins—into a platform for producing new categories of medicines.
|
|
Fifteen years ago, Bancel had his doubts. At the time, there were no approved mRNA-based products on the market, and most scientists would have agreed that mRNA was too unstable to form the basis of a new class of medical treatments. In fact, the entire biotech industry had bet—successfully—on manipulating another, more reliable genetic material: DNA.
|
|
“It was crazy to think of using mRNA as a drug,” Bancel reflects. But that was before a fateful meeting forced him to look at the genetic material in a different way, and realize that with the right manipulation, mRNA provided a way to make drugs that were never possible with existing strategies. Now, he believes that nearly any protein drug made today with existing, recombinant DNA technology can also be made using mRNA.
|
|
Read the full story here.
|
|
|
|
| |
|
|
|
| |
| |
SPONSORED BY WITH COVERAGE
|
Why Gopuff replaced its insurance broker with us.
|
|
|
|
Gopuff's legal team cut premiums by 20% while improving their coverage. WithCoverage is the insurance broker and platform for companies paying six figures a year for business insurance. Start with a free, confidential risk analysis.
|
|
Request Your Confidential Risk Analysis
|
|
|
|
| |
|
|
|
|
|
|
|
| |
| |
SPONSORED
|
TIME100 Most Influential Companies is expanding
|
|
|
|
TIME100 Most Influential Companies 2027 entries are now open.
|
|
With new Exceptional Workplaces categories, the TIME100 Companies publication is expanding to recognize businesses pioneering new approaches to how people work, from flexible and hybrid work to technology integration and career development.
|
|
Because it’s no longer just what you do, but how you do it.
|
|
Submit your company.
|
|
|
|
| |
|
|
|
| |
Click to sign up.
|
|
|
|
|